Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01115387 · ClinicalTrials.gov registry record

GARM II: A Study on the Genetics of Age-related Maculopathy

A clinical trial of Age-related Macular Degeneration and Age-related Maculopathy, sponsored by University of California, Los Angeles.

Active
Registry status
603
Enrollment target
2
Study locations

NCT01115387 is a study of Age-related Macular Degeneration and Age-related Maculopathy that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 603 participants, below the 1,500-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (60% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01115387, a study of Age-related Macular Degeneration and Age-related Maculopathy, is active but no longer recruiting, sponsored by University of California, Los Angeles.

ACTIVE NOT RECRUITING
Registry status
603 participants
Enrollment target
2
Study locations

Study Summary

The original study (GARM I) has been conducted for more than 18 years at the University of Pittsburgh Medical Center (UPMC). GARM II is a nationwide research study about age-related macular degeneration in the next generation of adults (49 to 65 years old). The purpose of this study is to identify the hereditary and exposure risk factors that lead to the development of ARM (Age related maculopathy). Participants will communicate with the research staff through a protected and confidential website and use this website to complete a number of questionnaires during the course of the study (see below). For genetic analyses, the participants will mail in easily self-collected saliva samples in special containers. Eye photographs and eye health records are sent to the research center from local sources through the Internet. Individuals are not expected to come to UCLA in order to participate. https://jseiclinres.jsei.ucla.edu/garm/ Participants will be expected to answer questionnaires or surveys about medical history, ocular history and visual symptoms, family history, smoking, dietary supplements and light exposure.

Conditions Studied

Age-related Macular Degeneration Age-related Maculopathy

Interventions

  • OTHER Observational-1
  • OTHER Observational-2

Study Locations (2)

California

  • Jules Stein Eye Institute, Dept. of Ophthalmology David Geffen School of Medicine at UCLA - Los Angeles

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 603 participants
Start Date 2011-10-06
Est. Completion 2027-03

Sponsor

University of California, Los Angeles

897 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01115387

The ClinicalTrials.gov registry entry for NCT01115387 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 603 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,500-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (60% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Observational-1 is the first listed.

NCT01115387 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01115387 about?

NCT01115387 is a clinical study titled "GARM II: A Study on the Genetics of Age-related Maculopathy". The original study (GARM I) has been conducted for more than 18 years at the University of Pittsburgh Medical Center (UPMC). GARM II is a nationwide research study about age-related macular degeneration in the next generation of adults (49 to 65 years old). The purpose of this study is to identify t...

What is the current status of trial NCT01115387?

This trial is currently active not recruiting. The enrollment target is 603 participants. The study started on 2011-10-06. Estimated completion is 2027-03.

What conditions does trial NCT01115387 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration, Age-related Maculopathy.

What interventions are being tested in trial NCT01115387?

The interventions under investigation include: Observational-1 (OTHER), Observational-2 (OTHER).

Who is sponsoring clinical trial NCT01115387?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01115387 being conducted?

This trial has 2 study locations across California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Age-related Macular Degeneration

All registered trials for this condition

Age-related Maculopathy

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.